Related references
Note: Only part of the references are listed.Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma
Shruti Gupta et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
CAR T-cell therapy: Full speed ahead
David Sermer et al.
HEMATOLOGICAL ONCOLOGY (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Toxicities of CD19 CAR-T cell immunotherapy
Alexandre V. Hirayama et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Tocilizumab and refractory Takayasu disease: Four case reports and systematic review
Paul Decker et al.
AUTOIMMUNITY REVIEWS (2018)
Chimeric Antigen Receptor T Cell Therapy and the Kidney What the Nephrologist Needs to Know
Kenar D. Jhaveri et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Post-Transplantation Lymphoproliferative Disorders in Adults
Daan Dierickx et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience
Anthea C. Peters et al.
TRANSPLANTATION (2018)
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial
Ralf U. Trappe et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Post-transplant lymphoproliferative disorders
Vikas R. Dharnidharka et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Severe hepatitis associated with tocilizumab in a patient with rheumatoid arthritis
Majd Alfreijat et al.
RHEUMATOLOGY (2013)
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
Ralf Trappe et al.
LANCET ONCOLOGY (2012)
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders:: results of a prospective multicenter phase 2 study
S Choquet et al.
BLOOD (2006)
Treatment of PTLD with rituximab or chemotherapy
RL Elstrom et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Share Paper
